555 results on '"Koschinsky, Marlys L."'
Search Results
2. Lipoprotein(a) in Cardiovascular Risk Assessment
3. Contributors
4. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice
5. Molecular Mechanisms of Lipoprotein(a) Pathogenicity: Tantalizing Clues and Unanswered Questions
6. Fibrinogen and plasma clot properties are associated with apolipoprotein B and apolipoprotein B-containing lipoproteins in Africans
7. What's next for lipoprotein(a)? A national lipid association report from an expert panel discussion
8. High levels of lipoprotein(a) in transgenic mice exacerbate atherosclerosis and promote vulnerable plaque features in a sex-specific manner
9. Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor
10. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society
11. Atherogenic Lipoprotein(A) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation
12. Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis
13. Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis
14. The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target
15. Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology
16. Lipoprotein(a) and cardiovascular disease.
17. Lipoprotein (a): Principles from Bench to Bedside
18. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis
19. Abstract 11904: Lipoprotein(a) Integrates Monocyte-Mediated Thrombosis and Inflammation in Atherosclerotic Cardiovascular Disease
20. Lipoprotein(a): Expanding our knowledge of aortic valve narrowing
21. Contributors
22. Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk.
23. ApoA and ApoB Interact Noncovalently Within Hepatocytes: Implications for Regulation of Lp(a) (Lipoprotein[a]) Levels by Modulation of ApoB Secretion
24. Interaction of Autotaxin With Lipoprotein(a) in Patients With Calcific Aortic Valve Stenosis
25. Long Non-coding RNA MIAT Controls Advanced Atherosclerotic Lesion Formation and Plaque Destabilization
26. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association
27. Lipoprotein(a)
28. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association
29. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
30. Lipoprotein (a): Principles from Bench to Bedside
31. Long Noncoding RNA MIAT Controls Advanced Atherosclerotic Lesion Formation and Plaque Destabilization
32. JCL roundtable—Lipoprotein(a): The emerging risk factor
33. Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal
34. Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a)
35. Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins αMβ2 and αVβ3
36. Pathophysiology and Risk of Atrial Fibrillation Detected after Ischemic Stroke (PARADISE): A Translational, Integrated, and Transdisciplinary Approach
37. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a) 1
38. OXIDIZED PHOSPHOLIPIDS ON APOLIPOPROTEIN(A) ARE ONLY PRESENT ON HUMAN LP(A): IMPLICATIONS FOR UNDERSTANDING LP(A) ATHEROGENICITY
39. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease
40. Lipoprotein(a) induces caspase-1 activation and IL-1 signaling in human macrophages
41. Abstract 116: Variation In Lipoprotein (a) Level Reduction With Potent Lipid Lowering: An Analysis Of The Cholesterol Reduction And Residual Risk In Diabetes Study
42. 5 - Lipoprotein(a) in Cardiovascular Risk Assessment
43. Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye?
44. From the EAS:* frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society
45. Surface LDLR is a major receptor for lipoprotein(a) clearance in male mice lacking PCSK9
46. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society
47. LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: A proof-of-concept study
48. PCSK9 deficiency results in a specific shedding of excess LDLR in female mice only: Role of hepatic cholesterol
49. Intracoronary Stents: Medical Devices at the Interface of Biology and Electrochemistry
50. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.